CAHIC(600195)

Search documents
中牧实业股份有限公司第九届监事会2025年第一次临时会议决议公告
Shang Hai Zheng Quan Bao· 2025-08-19 19:41
Core Viewpoint - Company plans to exercise its preemptive subscription rights to participate in the convertible bond issuance by Xiamen Jindawei Group Co., Ltd, with an investment amount not exceeding RMB 241.42 million [2][5][19] Investment Overview - The convertible bonds issued by Jindawei aim to raise up to RMB 1.29 billion [6] - Company holds 113,927,593 shares of Jindawei, representing an 18.68% stake, and thus has the right to participate in the bond issuance [2][6] - The investment amount planned for the subscription is capped at RMB 241.42 million, which is 4.39% of the company's audited net assets for 2024 and 4.33% of the unaudited net assets for Q1 2025 [7][19] Approval Process - The proposal to exercise the preemptive rights was approved in the temporary meetings of both the board of directors and the supervisory board on August 18, 2025, with unanimous support [14][19] - The company is not required to follow the related party transaction review process for this investment [14] Investment Details - The investment will be made using the company's own funds [8] - The investment is categorized as a securities investment under the Securities Law [9] - The investment period is set for 12 months from the board's approval [13] Impact on Company - The investment will not significantly affect the company's operational cash flow or its main business activities [19] - The company plans to classify the convertible bonds as financial assets measured at fair value, with changes recorded in current profits and losses [19]
中牧股份:第九届监事会2025年第一次临时会议决议公告

Zheng Quan Ri Bao· 2025-08-19 13:41
(文章来源:证券日报) 证券日报网讯 8月19日晚间,中牧股份发布公告称,公司第九届监事会2025年第一次临时会议审议通过 了《关于公司行使优先配售权参与认购厦门金达威集团股份有限公司向不特定对象发行可转换公司债券 的议案》。 ...
中牧股份(600195) - 中牧实业股份有限公司第九届监事会2025年第一次临时会议决议公告
2025-08-19 11:45
股票代码:600195 股票简称:中牧股份 编号:临 2025-023 中牧实业股份有限公司 第九届监事会 2025 年第一次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司监事会 2025 年 8 月 20 日 中牧实业股份有限公司(以下简称"公司"或"中牧股份")第九届监事会 2025 年第一次临时会议通知于 2025 年 8 月 14 日通过公司电子办公系统、电子邮件等形 式发出,会议于 2025 年 8 月 18 日以通讯方式召开,会议应到监事 3 名,实到监事 3 名。会议由监事会主席侯士忠先生主持,符合《公司法》《公司章程》的规定。 经与会监事认真审议,会议表决通过如下议案: 关于公司行使优先配售权参与认购厦门金达威集团股份有限公司向不特定对象 发行可转换公司债券的议案 表决结果:3 票同意,0 票反对,0 票弃权。 监事会认为:厦门金达威集团股份有限公司向不特定对象发行可转换公司债券, 募集金额不超过人民币 129,239.48 万元(含本数)。截至目前,公司持有厦门金达 威 ...
中牧股份(600195) - 中牧实业股份有限公司关于行使优先配售权参与认购厦门金达威集团股份有限公司向不特定对象发行可转换公司债券的公告
2025-08-19 11:36
股票代码:600195 股票简称:中牧股份 编号:临 2025-022 中牧实业股份有限公司关于 行使优先配售权参与认购厦门金达威集团股份有限 公司向不特定对象发行可转换公司债券的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●投资种类:证券投资 ●投资金额:中牧实业股份有限公司(以下简称"公司")计划参与认购厦 门金达威集团股份有限公司(以下简称"金达威",股票代码:002626)可转债 的投资本金不超过人民币 24,141.93 万元(含本数,最终认购数量及认购资金以 实际成交为准)。 ●已履行的审议程序:2025 年 8 月 18 日,公司第九届董事会 2025 年第十 次临时会议、第九届监事会 2025 年第一次临时会议审议通过了《关于公司行使 优先配售权参与认购厦门金达威集团股份有限公司向不特定对象发行可转换公 司债券的议案》。 ●特别风险提示:根据《企业会计准则》规定,公司拟将持有的可转换债券 投资作为一个整体进行评估,拟将持有的金达威可转换债券分类为以公允价值计 量且其变动计入当期损益的金 ...
动物疫苗概念涨2.47%,主力资金净流入这些股
Zheng Quan Shi Bao Wang· 2025-08-19 09:09
Group 1 - The animal vaccine concept sector rose by 2.47%, ranking second among concept sectors, with 12 stocks increasing in value, including Shenlian Biological which hit a 20% limit up [1] - Leading stocks in the sector included Yongshun Biological, Xianfeng Holdings, and Biological Shares, which rose by 9.35%, 8.44%, and 2.92% respectively [1] - The sector experienced a net outflow of 0.31 billion yuan in main funds, with 12 stocks seeing net inflows, and five stocks receiving over 10 million yuan in net inflows [1] Group 2 - Shenlian Biological, with a net inflow of 20.03%, had the highest main fund inflow of 20 million yuan, followed by Biological Shares and Haizheng Pharmaceutical with net inflows of 17.39 million yuan and 17.13 million yuan respectively [2] - The top three stocks by main fund inflow ratio were Shenlian Biological at 6.76%, Ronioushan at 6.52%, and Zhongmu Shares at 5.23% [2][3] - Stocks such as Kanghua Biological, Jinhai Biological, and Dabeinong experienced significant net outflows, with Kanghua Biological seeing a decline of 1.35% and a net outflow of 47.41 million yuan [3]
中牧股份(600195.SH):拟行使优先配售权参与认购金达威可转债
Ge Long Hui A P P· 2025-08-19 07:49
Core Viewpoint - The company Zhongmu Co., Ltd. (600195.SH) announced that its associate company Jindawei is issuing convertible bonds to unspecified investors, raising up to RMB 1,292.39 million, including the principal amount [1] Group 1: Company Actions - Zhongmu Co., Ltd. holds 113,927,593 shares in Jindawei, representing an 18.68% ownership stake, and has the preferential subscription right for the convertible bonds being issued [1] - The company plans to exercise its preferential subscription right to participate in the subscription of Jindawei's convertible bonds, with an investment amount not exceeding RMB 241.42 million, including the principal [1] Group 2: Financial Impact - The planned investment in Jindawei's convertible bonds will account for 4.39% of the company's audited net assets for the year 2024 and 4.33% of the company's unaudited net assets for the first quarter of 2025 [1]
兰州高新区政策红利赋能生物医药产业启新程
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-08-18 13:30
Core Viewpoint - The Gansu Provincial Science and Technology Department and other six departments have issued a plan to support the Lanzhou High-tech Zone in promoting the biopharmaceutical industry, aiming to enhance its high-quality development and establish it as a significant biopharmaceutical hub in China [1] Group 1: Industry Development - The Lanzhou High-tech Zone has developed a complete biopharmaceutical industry system, including modern traditional Chinese medicine, biological products, medical devices, and biotechnology services, with over 200 enterprises and a stable industry chain output value of approximately 24 billion [2] - The zone has ranked among the top 50 in the national comprehensive competitiveness evaluation of biopharmaceutical industrial parks for two consecutive years, and its biopharmaceutical manufacturing innovation cluster has been recognized as one of 46 national innovation industry clusters [2] Group 2: Policy Support - The newly issued plan focuses on key areas such as technology research and development, resource supply, and market access, creating a comprehensive support system from laboratory to industrialization [3] - By the end of 2027, the Lanzhou High-tech Zone aims to achieve a total output value of over 30 billion in the biopharmaceutical industry, develop 2-3 innovative drugs, 3-5 new medical device products, and cultivate 2-3 major products with annual sales exceeding 500 million [3] Group 3: Company Initiatives - Companies in the Lanzhou High-tech Zone are seizing opportunities to accelerate their development, with firms like Zhongnong Weite focusing on new vaccine research and aiming for multiple new veterinary drug registrations [4] - Lanzhou Mingde Pharmaceutical is advancing its research on animal-derived collagen protein, leveraging policy support to enhance its confidence in the high-end medical device sector [4] - Various enterprises are making significant progress in their respective fields, with Haotian Technology becoming a supplier for 12 of the world's top 50 pharmaceutical companies and Zhongnong Weite passing GMP acceptance for its new production line [4]
动物保健板块8月18日涨2.2%,申联生物领涨,主力资金净流出737.37万元
Zheng Xing Xing Ye Ri Bao· 2025-08-18 08:38
证券之星消息,8月18日动物保健板块较上一交易日上涨2.2%,申联生物领涨。当日上证指数报收于 3728.03,上涨0.85%。深证成指报收于11835.57,上涨1.73%。动物保健板块个股涨跌见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688098 | 申联生物 | 12.83 | 20.02% | 13.27万 | 1.69 Z | | 300871 | 回盛生物 | 24.26 | 7.87% | 30.00万 | 7.20亿 | | 838275 | 驱动力 | 10.02 | 6.60% | 4.35万 | 4273.62万 | | 002141 | 贤丰控股 | 3.91 | 4.27% | 1 85.59万 | 3.38亿 | | 839729 | 永顺生物 | 9.95 | 3.65% | 3.11万 | 3066.40万 | | 871970 | 大禹生物 | 9.98 | 3.42% | 2.96万 | 2928.24万 | | 300119 | 瑞普生物 | ...
动物保健板块8月15日涨3.86%,申联生物领涨,主力资金净流入4948.27万元
Zheng Xing Xing Ye Ri Bao· 2025-08-15 08:37
Core Insights - The animal health sector experienced a significant increase of 3.86% on August 15, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] Stock Performance - Shenlian Biological (688088) saw a closing price of 10.69, with a remarkable increase of 19.98% and a trading volume of 435,300 shares, amounting to a transaction value of 441 million yuan [1] - Other notable performers included: - Biological Shares (600201) with a closing price of 8.93, up 6.06% [1] - Ruipu Biological (300119) with a closing price of 22.78, up 5.56% [1] - KQ Biological (688526) with a closing price of 17.24, up 2.44% [1] Capital Flow - The animal health sector saw a net inflow of 49.48 million yuan from institutional investors, while retail investors contributed a net inflow of 40.08 million yuan [1] - Notably, retail funds experienced a net outflow of 89.56 million yuan [1] Detailed Capital Flow Analysis - Shenlian Biological had a net inflow of 54.78 million yuan from institutional investors, while it faced a net outflow of 41.10 million yuan from speculative funds [2] - Biological Shares had a net inflow of 14.26 million yuan from institutional investors, with a net outflow of 33.08 million yuan from speculative funds [2] - Ruipu Biological recorded a net inflow of 1.78 million yuan from institutional investors, while speculative funds saw a net outflow of 16.93 million yuan [2]
动保行业研究框架:行业回归创新驱动,宠物药品及出海拓展成长空间
Guohai Securities· 2025-08-13 15:28
Investment Rating - The report does not explicitly state an investment rating for the animal health industry, but it highlights potential growth areas such as pet pharmaceuticals and international expansion [1]. Core Insights - The animal health industry is experiencing a slowdown in growth, with increasing competition leading to a "Matthew Effect" where larger companies gain more market share at the expense of smaller firms [3][39]. - The industry is shifting back to a research and development-driven model, with innovation becoming crucial for future growth [4][83]. - The pet pharmaceutical market and international expansion are identified as key areas for long-term growth, with pet medical consumption projected to reach approximately 84 billion yuan in 2024 [5][78]. Summary by Sections 1. Overview of the Animal Health Industry - The animal health industry, also known as the veterinary drug industry, includes a wide range of products such as vaccines, antibiotics, and feed additives [11][12]. - The market size has grown from 50.395 billion yuan in 2019 to 69.651 billion yuan in 2023, with a CAGR of 8.43% [3][12]. 2. Increasing Competition and Market Dynamics - The industry is facing a slowdown in growth, with sales increasing from 62.095 billion yuan in 2020 to 69.651 billion yuan in 2023, while average gross profit has decreased from 21.998 billion yuan to 21.297 billion yuan [3][39]. - The "Matthew Effect" is evident as larger companies leverage their product portfolios and R&D investments to capture more market share [3][52]. 3. Shift Towards R&D and Innovation - The industry is moving away from its cyclical nature, with a focus on integrated strategies and innovation to counteract competitive pressures [4][69]. - The average profit per head in self-breeding pig farming is expected to improve significantly in 2024, indicating potential for recovery in related sectors [4][62]. 4. Growth Opportunities in Pet Pharmaceuticals and Exports - The pet medical market is projected to grow rapidly, with a significant increase in demand for preventive care and treatment as pet owners become more health-conscious [5][78]. - The report highlights the successful export of domestic pet pharmaceuticals, marking a breakthrough in international markets [5][78]. 5. Key Companies to Watch - Companies such as 瑞普生物 (Reap Bio), 科前生物 (KQ Bio), and 回盛生物 (Hui Sheng Bio) are recommended for attention due to their innovative approaches and market positioning [6].